CIK 0001439222
- Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-12-03 | FOUSE JACQUALYN A Director | Grant or award · Stock option (right to buy) | +16,000 | 16,000 | ||
| 2017-12-01 | Schenkein David P Chief Executive Officer | Option exercise · Stock option (right to buy) | −6,000 | 38,837 | ||
| 2017-12-01 | Schenkein David P Chief Executive Officer | Option exercise | +6,000 | $0.30 | $2K | 6,000 |
| 2017-12-01 | Schenkein David P Chief Executive Officer | Sale | −5,600 | $61.51 | $344K | 400 |
| 2017-12-01 | Schenkein David P Chief Executive Officer | Sale | −400 | $62.08 | $25K | 0 |
| 2017-12-01 | Schenkein David P Chief Executive Officer | Option exercise · Stock option (right to buy) | −6,000 | 20,656 | ||
| 2017-12-01 | Biller Scott Chief Scientific Officer | Option exercise | +2,146 | $31.64 | $68K | 8,410 |
| 2017-12-01 | Biller Scott Chief Scientific Officer | Sale | −600 | $59.89 | $36K | 7,810 |
| 2017-12-01 | Biller Scott Chief Scientific Officer | Sale | −846 | $60.63 | $51K | 6,964 |
| 2017-12-01 | Biller Scott Chief Scientific Officer | Sale | −700 | $61.76 | $43K | 6,264 |
| 2017-12-01 | Biller Scott Chief Scientific Officer | Option exercise · Stock options (right to buy) | −2,146 | 30,039 | ||
| 2017-11-14 | Cantley Lewis Clayton Jr. Director | Sale | −691 | $59.36 | $41K | 81,703 |
| 2017-11-14 | Cantley Lewis Clayton Jr. Director | Sale | −691 | $59.36 | $41K | 81,743 |
| 2017-11-14 | Cantley Lewis Clayton Jr. Director | Sale | −309 | $60.46 | $19K | 81,394 |
| 2017-11-14 | Cantley Lewis Clayton Jr. Director | Sale | −309 | $60.46 | $19K | 81,434 |
| 2017-11-13 | Cantley Lewis Clayton Jr. Director | Sale | −1,000 | $62.07 | $62K | 82,394 |
| 2017-11-13 | Cantley Lewis Clayton Jr. Director | Sale | −1,000 | $62.07 | $62K | 82,434 |
| 2017-11-01 | Biller Scott Chief Scientific Officer | Option exercise | +2,146 | $31.64 | $68K | 8,410 |
| 2017-11-01 | Biller Scott Chief Scientific Officer | Sale | −100 | $65.45 | $7K | 8,310 |
| 2017-11-01 | Biller Scott Chief Scientific Officer | Sale | −200 | $63.62 | $13K | 8,110 |
Page 70 of 80 · 1,590 trades